The prognostic value of free triiodothyronine/free thyroxine ratio in short-term outcomes after left ventricular assist device implantation

Year 2024, , 241 - 247, 14.06.2024

Arzu Yazar Aykun Hakgör

https://doi.org/10.5798/dicletip.1501320

Abstract

Background: Despite advancement in technology adverse events after left ventricular assist device(LVAD) implantation continue to be the main barrier to more widespread use of it. Therefore, it is vital to identify prognostic factors to reduce adverse cardiac events after LVAD implatation. Thyroid dysfunction is associated with a poor prognosis in individuals with heart failure. The objective of this study is to examine the correlation between thyroid hormones and adverse cardiovascular events following LVAD implantation.
Method and Results: The study included a total of 36 patients, with an average age of 60 ± 9 years, of which 77.7% were male. Although there was no significant relationship between TSH and FT3 levels and post-operative adverse events(p>0.05 for both), there was a significant association between FT3/FT4 and all-cause and cardiovascular mortality(p<0.001 for both). ROC analysis revealed that FT3/FT4 values lower than 1 were significantly associated with adverse events(all p < 0.05). There was no significant difference between the two groups in terms of age, gender, BMI, etiology of heart failure, EF, sPAP, smoking status and the presence of comorbid diseases, BNP, TSH and FT3 levels(p>0.05 for all). All-cause mortality, cardiac mortality, arrhythmia prevelance, vasopressor need(day) and duration of ICU stay were significantly higher in FT3/FT4 < 1 group(all p < 0.05).
Conclusion: Our findings suggest that FT3/FT4 ratio might be useful as a biomarker of short-term adverse clinical outcomes in patients who underwent LVAD implantation.

Keywords

Left ventricular assist device, Heart failure, Thyroid disfunction; FT3/FT4 ratio; Cardiac mortality

References

• 1.Razvi S, Jabbar A, Pingitore A, et al. Thyroidhormones and cardiovascular function and diseases.Journal of the American College of Cardiology. 2018;71(16):1781-96.
• 2.PR L. Thyroid-pituitary interaction: feedbackregulation of thyrotropin secretion by thyroidhormone. N Engl J Med. 1982;306:23-32.
• 3.Suzuki Y, Nanno M, Gemma R, Yoshimi T. Plasmafree fatty acids, inhibitor of extrathyroidalconversion of T4 to T3 and thyroid hormone binding inhibitor in patients with various nonthyroidalillnesses. Endocrinologia japonica. 1992;39(5):445-53.
• 4.Mitchell JE, Hellkamp AS, Mark DB, et al. Thyroidfunction in heart failure and impact on mortality.JACC: Heart Failure. 2013;1(1):48-55.
• 5.Conrad N, Judge A, Tran J, et al. Temporal trendsand patterns in heart failure incidence: a population-based study of 4 million individuals. The Lancet.2018;391(10120):572-80.
• 6.Murphy SP, Ibrahim NE, Januzzi JL. Heart failurewith reduced ejection fraction: a review. Jama.2020;324(5):488-504.
• 7.Mehra MR, Goldstein DJ, Cleveland JC, Cowger JA,Hall S, Salerno CT, et al. Five-year outcomes inpatients with fully magnetically levitated vs axial-flow left ventricular assist devices in theMOMENTUM 3 randomized trial. JAMA.2022;328(12):1233-42.
• 8. Kilic A, Macickova J, Duan L, et al. Machine learning approaches to analyzing adverse events followingdurable LVAD implantation. The Annals of ThoracicSurgery. 2021;112(3):770-7.
• 9.Grais IM, Sowers JR. Thyroid and the heart. TheAmerican journal of medicine. 2014;127(8):691-8.
• 10.Klein I, Ojamaa K. Thyroid hormone and thecardiovascular system. New England Journal ofMedicine. 2001;344(7):501-9.
• 11.Fukuyama K, Ichiki T, Takeda K, et al.Downregulation of vascular angiotensin II type 1receptor by thyroid hormone. Hypertension.2003;41(3):598-603.
• 12. Carrillo-Sepúlveda MA, Ceravolo GS, Fortes ZB, et al. Thyroid hormone stimulates NO production viaactivation of the PI3K/Akt pathway in vascularmyocytes. Cardiovascular research.2010;85(3):560-70.
• 13.Tang Y-D, Kuzman JA, Said S, et al. Low thyroidfunction leads to cardiac atrophy with chamberdilatation, impaired myocardial blood flow, loss ofarterioles, and severe systolic dysfunction.Circulation. 2005;112(20):3122-30.
• 14.Pantos C, Dritsas A, Mourouzis I, et al. Thyroidhormone is a critical determinant of myocardialperformance in patients with heart failure: potentialtherapeutic implications. European Journal ofEndocrinology. 2007;157(4):515-20.
• 15.Wang W, Guan H, Fang W, et al. Freetriiodothyronine level correlates with myocardialinjury and prognosis in idiopathic dilatedcardiomyopathy: evidence from cardiac MRI andSPECT/PET imaging. Scientific reports.2016;6(1):39811.
• 16.Rhee CM, Curhan GC, Alexander EK, Bhan I,Brunelli SM. Subclinical hypothyroidism andsurvival: the effects of heart failure and race. TheJournal of Clinical Endocrinology & Metabolism.2013;98(6):2326-36.
• 17.Cappola AR, Fried LP, Arnold AM, et al. Thyroidstatus, cardiovascular risk, and mortality in olderadults. Jama. 2006;295(9):1033-41.
• 18.Gencer B, Collet T-H, Virgini V, et al. Subclinicalthyroid dysfunction and the risk of heart failureevents: an individual participant data analysis from6 prospective cohorts. Circulation.2012;126(9):1040-9.
• 19.Bielka A, Kalinowski M, Gawlikowski M, et al.Thyroid Function at Left Ventricular Assist Device(LVAD) Implantation Predicts Prognosis DuringLVAD Support. The Journal of Heart and LungTransplantation. 2022;41(4):S121-S2.